重视化thalidomide衍生物的抗血管生成机制
Johannes Sievers1, Rabea Voget1, Feiteng Lu2
1Pharmaceutical Institute, Pharmaceutical and Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany.
Bioorganic & medicinal chemistry letters
|June 25, 2024
概括
免疫调节药物 (IMiDs) 中的增强了抗血管原作用,但四化不会诱导新基质的降解. 这表明IMiD驱动的抗血管生成的独特机制超出了基质降解.
科学领域:
- 药用化学 医学化学
- 药物开发 药物开发
- 分子药理学分子药理学
背景情况:
- 的结合是药物开发中的一个关键策略.
- 免疫调节药物 (IMiDs) 与大脑结合,诱导E3结合酶复合体中的新型活性.
- IMiDs的四化增强了它们的抗血管性质.
研究的目的:
- 研究化IMiDs抗血管性活性背后的机制.
- 为了确定新基质降解是否对化IMiDs的抗血管效应负责.
- 探索在非传统IMiD类似物中的结构-活性关系.
主要方法:
- 合成和评估八种thalidomide类似物 (非化和四化).
- 对新基质降解的测试 (IKZF3,GSPT1,CK1α,SALL4).
- 素扫描本扎米多谷物胺IMiD类似物.
- 内皮细胞管形成试验,以评估血管生成抑制.
主要成果:
- 四化thalidomide类似物没有诱导新型基质的降解.
- 化IMiDs的抗血管性活性独立于新基质降解.
- 在本扎米多谷物胺类同类药物中没有发现新的血管生成抑制剂.
- 证实了IMID诱导的抗血管生成的狭窄结构-活性窗口.
结论:
- 化IMiDs的抗血管效应并非由新基质降解介导.
- 在增强IMiD抗血管生成中的作用是通过基质降解以外的机制运作.
- IMiD介导的抗血管生成的结构-活性关系是高度特定的.
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Mechanism of Angiogenesis
5.4K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.4K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Antihypertensive Drugs: Thiazide-Class Diuretics
598
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
598
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K


